GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2007

Genentech Deploys Sangamo Platform for Protein Pharmaceutical Production

  • Sangamo BioSciences will provide Genentech with access to  its zinc finger DNA-binding protein (ZFP) technology and will design and engineer ZFP nucleases (ZFN™).

    “Our technology has the potential to change the speed and efficiency of cell engineering to meet the increased demand for proteins in a variety of industries, including pharmaceutical protein manufacturing,” adds Lamphier.

    Genentech will use Sangamo’s platform to evaluate and generate cell lines with characteristics for protein pharmaceutical production purposes.

    “We have engineered ZFNs to facilitate the efficient generation of production cell lines with altered traits,” says Edward Lanphier, Sangamo’s president and CEO.

    Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting of a particular gene or genes of interest, according to Sangamo. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »